|
Pfizer and BioNTech announce further details on collaboration to accelerate global COVID-19 vaccine development
|
10 April 2020 |
|
Pfizer Vaccines launches global Centers of Excellence Network
|
23 January 2020 |
|
Theravance Biopharma and Pfizer Inc. enter global license agreement for skin-targeted, locally-acting pan-Janus kinase (JAK) inhibitor program
|
23 December 2019 |
|
FDA approves Pfizer's biosimilar, ABRILADA™ (adalimumab-afzb) for multiple inflammatory conditions
|
02 December 2019 |
|
Mylan and Pfizer announce Viatris as the new company name in the planned Mylan-Upjohn combination
|
13 November 2019 |
|
OPKO and Pfizer announce positive Phase 3 top-line results for somatrogon
|
24 October 2019 |
|
Akcea and Pfizer Inc. announce licensing agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx
|
07 October 2019 |
|
Ian Read to retire as Executive Chairman of Pfizer's Board of Directors; Chief Executive Officer Dr. Albert Bourla named Chairman
|
30 September 2019 |
|
Pfizer invests half billion dollars to advance state-of-the-art gene therapy facility in Sanford, North Carolina
|
29 August 2019 |
|
The Pfizer Foundation invests in 20 organizations tackling infectious diseases and antimicrobial resistance
|
21 August 2019 |
|
Mylan and Upjohn, a division of Pfizer, to combine, creating a new champion for global health uniquely positioned to fulfill the world's need for medicine
|
29 July 2019 |
|
Pfizer completes acquisition of Therachon
|
05 July 2019 |
|
Jeff Settleman, Ph.D., joins Pfizer to lead Oncology Research & Development
|
07 June 2019 |
|
Pfizer announces top-line results from Phase 3 Trial of LYRICA® (pregabalin) in primary generalized tonic-clonic seizures
|
24 May 2019 |
|
Pfizer and Lilly announce top-line results from long-term Phase 3 study of tanezumab in patients with osteoarthritis
|
22 April 2019 |
|
Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics
|
21 March 2019 |
|
Ochsner Health System and Pfizer partner to develop innovative models for clinical trials
|
19 February 2019 |
|
The Union for International Cancer Control and Pfizer announce new phase of global grants initiative supporting metastatic breast cancer patients
|
08 February 2019 |
|
Pfizer receives positive CHMP opinion for Vizimpro® (dacomitinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR-activating mutations
|
01 February 2019 |
|
Pfizer and Lilly announce top-line results from second Phase 3 study of tanezumab in osteoarthritis pain
|
29 January 2019 |